Literature DB >> 18718081

[Role of CD4(+) CD25(high) T cells in the pathogenesis of idiopathic thrombocytopenic purpura].

Mi-Mi Shu1, Xing-Mei Cao, Wang-Gang Zhang.   

Abstract

This study was aimed to investigate the expression level of CD4(+) CD25(high) T cells in peripheral blood of patients with idiopathic thrombocytopenic purpura (ITP) before and after treatment and to explore its significance in pathogenesis of ITP. The expressions of CD4(+) CD25(high) T cells in peripheral blood of 20 ITP patients before treatment, 20 ITP patients after treatment and 14 normal individuals (control) were detected by immunofluorescence and flow cytometry. The result showed that the expression of CD4(+) CD25(high) in ITP group before treatment was evidently lower than that in treated ITP group and control (p < 0.01), but there was no remarkable difference between the treated ITP group and the control group p > 0.05). In conclusion, the expression of CD4(+) CD25(high) T cells in the ITP group before treatment was evidently lower than that in the control group, which becomes higher than before when the patients showed effective response to the treatment. Correlation of CD4(+) CD25(high) T cell expression rate in peripheral blood with platelet level was positive. Therefore the expression level of CD4(+) CD25(high) T cells can be used as an effective index to judge the ITP prognosis. Further study of CD4(+) CD25(high) T cells regarded as an immune target is needed.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18718081

Source DB:  PubMed          Journal:  Zhongguo Shi Yan Xue Ye Xue Za Zhi        ISSN: 1009-2137


  3 in total

1.  Alterations in immune cell subsets and their cytokine secretion profile in childhood idiopathic thrombocytopenic purpura (ITP).

Authors:  R M Talaat; A M Elmaghraby; S S Barakat; M El-Shahat
Journal:  Clin Exp Immunol       Date:  2014-05       Impact factor: 4.330

2.  Percentage of Memory B Lymphocytes and Regulatory T Lymphocytes in Peripheral Blood are Low but Not Predictive of Therapy outcomes in Newly Diagnosed Adult Patients with Primary Immune Thrombocytopenia.

Authors:  Mustafa Yilmaz; Semiha Ayhan
Journal:  Indian J Hematol Blood Transfus       Date:  2017-02-02       Impact factor: 0.900

3.  iTRAQ-based quantitative proteomics analysis of immune thrombocytopenia patients before and after Qishunbaolier treatment.

Authors:  Yanbo Wang; Shuanglian Wang; Cuiqin Gong; Haihua Bai
Journal:  Rapid Commun Mass Spectrom       Date:  2021-02-15       Impact factor: 2.586

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.